Adaptimmune Therapeutics Investor Relations Material
Latest events
Q1 2025
Adaptimmune Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Adaptimmune Therapeutics plc
Access all reports
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel cell therapies for cancer patients, particularly those with solid tumors. The company utilizes a proprietary cell therapy platform to engineer a patient's own cells to target and fight cancer. Adaptimmune is involved in several phase II clinical trials, including SPEARHEAD-1 for synovial sarcoma and SURPASS-3 for platinum-resistant ovarian cancer. Their research and development efforts are supported by strategic collaborations with entities like Genentech, Inc. and F. Hoffman-La Roche Ltd, among others, to further the development and potential commercialization of their therapies. The company is headquartered in Abingdon, United Kingdom, and its shares are listed on the NASDAQ.
Key slides for Adaptimmune Therapeutics plc
FDA Announcement
Adaptimmune Therapeutics plc
FDA Announcement
Adaptimmune Therapeutics plc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ADAP
Country
🇺🇸 United States